LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase

Nature Communications

Volumn 6, Issue , 2015, Pages

  Choi, Insup ^a   Kim, Beomsue ^a   Byun, Ji Won ^a   Baik, Sung Hoon ^b   Huh, Yun Hyun ^c   Kim, Jong Hyeon ^a   Mook Jung, Inhee ^a   Song, Woo Keun ^b   Shin, Joo Ho ^c   Seo, Hyemyung ^d   Suh, Young Ho ^e   Jou, Ilo ^a   Park, Sang Myun ^a   Kang, Ho Chul ^a   Joe, Eun Hye ^a  

^a Ajou University School of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Gwangju Institute of Science and Technology (GIST)   (South Korea)

^d Sungkyunkwan University   (South Korea)

^e Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; COFILIN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 7; EPIDERMAL GROWTH FACTOR RECEPTOR; F ACTIN; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 2; GLYCOGEN SYNTHASE KINASE 3BETA; LEUCINE RICH REPEAT KINASE 2; P21 ACTIVATED KINASE 1; PLATELET DERIVED GROWTH FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; URIDINE DIPHOSPHATE; VASODILATOR STIMULATED PHOSPHOPROTEIN; LRRK2 PROTEIN, HUMAN; LRRK2 PROTEIN, MOUSE; LRRK2 PROTEIN, RAT; PROTEIN SERINE THREONINE KINASE;

BRAIN; ENZYME ACTIVITY; GENE EXPRESSION; INJURY; MUTATION; PATHOGEN; REACTION KINETICS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AUTOPHOSPHORYLATION; BRAIN INJURY; CELL MOTILITY; CELL STRUCTURE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; FOCAL ADHESION; GENE MUTATION; GENE SILENCING; GENOTYPE; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MESENCEPHALON; MICROGLIA; MOUSE; NONHUMAN; PARKINSON DISEASE; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; MUTATION; PHOSPHORYLATION; RAT; TRANSGENIC MOUSE; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; BLOTTING, WESTERN; BRAIN INJURIES; CELL MOVEMENT; FOCAL ADHESION PROTEIN-TYROSINE KINASES; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; IMMUNOPRECIPITATION; LEUCINE-RICH REPEAT SERINE-THREONINE PROTEIN KINASE-2; MICE; MICE, TRANSGENIC; MICROGLIA; MUTATION; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RATS; WOUND HEALING;

EID: 84941635707     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9255     Document Type: Review

References (71)

1. Mata, I. F., Wedemeyer, W. J., Farrer, M. J., Taylor, J. P. & Gallo, K. A. LRRK2 in Parkinsons disease: protein domains and functional insights. Trends Neurosci. 29, 286-293 (2006).
2. Chan, D., Citro, A., Cordy, J. M., Shen, G. C. & Wolozin, B. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2). J. Biol. Chem. 286, 16140-16149 (2011).
3. Jaleel, M. et al. LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinsons disease mutants affect kinase activity. Biochem. J. 405, 307-317 (2007).
4. Parisiadou, L. et al. Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis. J. Neurosci. 29, 13971-13980 (2009).
5. Meixner, A. et al. A QUICK screen for Lrrk2 interaction partners-leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics. Mol. Cell. Proteomics 10, 001172 (2011).
6. Paisan-Ruiz, C., Washecka, N., Nath, P., Singleton, A. B. & Corder, E. H. Parkinsons disease and low frequency alleles found together throughout LRRK2. Ann. Hum. Genet. 73, 391-403 (2009).
7. Lesage, S. et al. LRRK2 G2019S as a cause of Parkinsons disease in North African Arabs. N. Engl. J. Med. 354, 422-423 (2006).
8. Ozelius, L. J. et al. LRRK2 G2019S as a cause of Parkinsons disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424-425 (2006).
9. Smith, W. W. et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA 102, 18676-18681 (2005).
10. MacLeod, D. et al. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593 (2006).
11. Lee, B. D., Dawson, V. L. & Dawson, T. M. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinsons disease. Trends Pharmacol. Sci. 33, 365-373 (2012).
12. Nimmerjahn, A., Kirchhoff, F. & Helmchen, F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318 (2005).
13. Davalos, D. et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 8, 752-758 (2005).
14. Li, Y., Du, X. F., Liu, C. S., Wen, Z. L. & Du, J. L. Reciprocal regulation between resting microglial dynamics and neuronal activity in vivo. Dev. Cell 23, 1189-1202 (2012).
15. Hines, D. J., Hines, R. M., Mulligan, S. J. & Macvicar, B. A. Microglia processes block the spread of damage in the brain and require functional chloride channels. Glia 57, 1610-1618 (2009).
16. Jeong, H. K. et al. Inflammatory responses are not sufficient to cause delayed neuronal death in ATP-induced acute brain injury. PLoS One 5, e13756 (2010).
17. Jeong, H. K., Ji, K., Min, K. & Joe, E. H. Brain inflammation and microglia: facts and misconceptions. Exp. Neurobiol. 22, 59-67 (2013).
18. El Khoury, J. et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 13, 432-438 (2007).
19. Kwan, W. et al. Mutant huntingtin impairs immune cell migration in Huntington disease. J. Clin. Invest. 122, 4737-4747 (2012).
20. Damani, M. R. et al. Age-related alterations in the dynamic behavior of microglia. Aging Cell 10, 263-276 (2011).
21. Hefendehl, J. K. et al. Homeostatic and injury-induced microglia behavior in the aging brain. Aging Cell 13, 60-69 (2014).
22. Kim, B. et al. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 7, e34693 (2012).
23. Moehle, M. S. et al. LRRK2 inhibition attenuates microglial inflammatory responses. J. Neurosci. 32, 1602-1611 (2012).
24. Lim, S. T. et al. Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation. Mol. Cell 29, 9-22 (2008).
25. Yamamoto, D. et al. FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways. Cell. Signal. 15, 575-583 (2003).
26. Mitra, S. K., Hanson, D. A. & Schlaepfer, D. D. Focal adhesion kinase: in command and control of cell motility. Nat. Rev. Mol. Cell Biol. 6, 56-68 (2005).
27. Dunty, J. M. et al. FERM domain interaction promotes FAK signaling. Mol. Cell. Biol. 24, 5353-5368 (2004).
28. Zheng, C. et al. Differential regulation of Pyk2 and focal adhesion kinase (FAK). The C-terminal domain of FAK confers response to cell adhesion. J. Biol. Chem. 273, 2384-2389 (1998).
29. Kornberg, L. J., Earp, H. S., Turner, C. E., Prockop, C. & Juliano, R. L. Signal transduction by integrins: increased protein tyrosine phosphorylation caused by clustering of beta 1 integrins. Proc. Natl Acad. Sci. USA 88, 8392-8396 (1991).
30. Guan, J. L., Trevithick, J. E. & Hynes, R. O. Fibronectin/integrin interaction induces tyrosine phosphorylation of a 120-kDa protein. Cell. Regul. 2, 951-964 (1991).
31. Shyy, J. Y. & Chien, S. Role of integrins in cellular responses to mechanical stress and adhesion. Curr. Opin. Cell Biol. 9, 707-713 (1997).
32. Luttrell, L. M., Daaka, Y. & Lefkowitz, R. J. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr. Opin. Cell Biol. 11, 177-183 (1999).
33. Sieg, D. J. et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat. Cell Biol. 2, 249-256 (2000).
34. Rozengurt, E. Mitogenic signaling pathways induced by G protein-coupled receptors. J. Cell Physiol. 213, 589-602 (2007).
35. Parsons, J. T., Martin, K. H., Slack, J. K., Taylor, J. M. & Weed, S. A. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 19, 5606-5613 (2000).
36. Haynes, S. E. et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat. Neurosci. 9, 1512-1519 (2006).
37. Schaller, M. D. et al. Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol. Cell Biol. 14, 1680-1688 (1994).
38. Slack-Davis, J. K. et al. Cellular characterization of a novel focal adhesion kinase inhibitor. J. Biol. Chem. 282, 14845-14852 (2007).
39. Golubovskaya, V. M. et al. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J. Med. Chem. 51, 7405-7416 (2008).
40. Golubovskaya, V. M. et al. Mitoxantrone targets the ATP-binding site of FAK, binds the FAK kinase domain and decreases FAK, Pyk-2, c-Src, and IGF-1R in vitro kinase activities. Anticancer Agents Med. Chem. 13, 546-554 (2013).
41. Pungaliya, P. P. et al. Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif. PLoS ONE 5, e13672 (2010).
42. Nichols, R. J. et al. Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinsons disease. Biochem. J. 424, 47-60 (2009).
43. Davies, P. et al. Comprehensive characterization and optimization of anti- LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies. Biochem. J. 453, 101-113 (2013).
44. Reith, A. D. et al. GSK2578215A; a potent and highly selective 2- arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor. Bioorg. Med. Chem. Lett. 22, 5625-5629 (2012).
45. Deng, X. et al. Characterization of a selective inhibitor of the Parkinsons disease kinase LRRK2. Nat. Chem. Biol. 7, 203-205 (2011).
46. Ramsden, N. et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinsons disease-related toxicity in human neurons. ACS Chem. Biol. 6, 1021-1028 (2011).
47. Lee, B. D. et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinsons disease. Nat. Med. 16, 998-1000 (2010).
48. Hall-Jackson, C. A. et al. Paradoxical activation of Raf by a novel Raf inhibitor. Chem. Biol. 6, 559-568 (1999).
49. Ehrenreiter, K. et al. Raf-1 regulates Rho signaling and cell migration. J. Cell Biol. 168, 955-964 (2005).
50. Moehle, M. S. et al. The G2019S LRRK2 mutation increases myeloid cell chemotactic responses and enhances LRRK2 binding to actin-regulatory proteins. Hum. Mol. Genet. 24, 4250-4267 (2015).
51. Caesar, M. et al. Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration. Neurobiol. Dis. 54, 280-288 (2013).
52. Etienne-Manneville, S. Actin and microtubules in cell motility: which one is in control? Traffic 5, 470-477 (2004).
53. Ilic, D. et al. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature 377, 539-544 (1995).
54. Leu, T. H. & Maa, M. C. Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397. Oncogene 21, 6992-7000 (2002).
55. Calalb, M. B., Polte, T. R. & Hanks, S. K. Tyrosine phosphorylation of focal adhesion kinase at sites in the catalytic domain regulates kinase activity: a role for Src family kinases. Mol. Cell. Biol. 15, 954-963 (1995).
56. Deramaudt, T. B. et al. FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion. Mol. Biol. Cell 22, 964-975 (2011).
57. Calalb, M. B., Zhang, X., Polte, T. R. & Hanks, S. K. Focal adhesion kinase tyrosine-861 is a major site of phosphorylation by Src. Biochem. Biophys. Res. Commun. 228, 662-668 (1996).
58. Tilghman, R. W. et al. Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J. Cell Sci. 118, 2613-2623 (2005).
59. Xie, Z., Sanada, K., Samuels, B. A., Shih, H. & Tsai, L. H. Serine 732 phosphorylation of FAK by Cdk5 is important for microtubule organization, nuclear movement, and neuronal migration. Cell 114, 469-482 (2003).
60. Smith, W. W. et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231-1233 (2006).
61. Liu, E., Cote, J. F. & Vuori, K. Negative regulation of FAK signaling by SOCS proteins. EMBO J. 22, 5036-5046 (2003).
62. Angers-Loustau, A. et al. Protein tyrosine phosphatase-PEST regulates focal adhesion disassembly, migration, and cytokinesis in fibroblasts. J. Cell Biol. 144, 1019-1031 (1999).
63. Manes, S. et al. Concerted activity of tyrosine phosphatase SHP-2 and focal adhesion kinase in regulation of cell motility. Mol. Cell. Biol. 19, 3125-3135 (1999).
64. Zheng, Y. et al. FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. Mol. Cell 35, 11-25 (2009).
65. Choi, I. et al. Pink1 deficiency attenuates astrocyte proliferation through mitochondrial dysfunction, reduced akt and increased p38 mapk activation, and downregulation egfr. Glia 61, 800-812 (2013).
66. Kim, J. H. et al. DJ-1 facilitates the interaction between STAT1 and its phosphatase, SHP-1, in brain microglia and astrocytes: a novel antiinflammatory function of DJ-1. Neurobiol. Dis 60C, 1-10 (2013).
67. Kim, K. S. et al. DJ-1 associates with lipid rafts by palmitoylation and regulates lipid rafts-dependent endocytosis in astrocytes. Hum. Mol. Genet 22, 4805-4817 (2013).
68. Kim, J. H. et al. Suppression of miR-155 expression in IFN-?-Treated astrocytes and microglia by DJ-1: a possible mechanism for maintaining SOCS1 expression. Exp. Neurobiol 23, 148-154 (2014).
69. Li, Y. et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinsons disease. Nat. Neurosci. 12, 826-828 (2009).
70. Pyo, H., Jou, I., Jung, S., Hong, S. & Joe, E. H. Mitogen-activated protein kinases activated by lipopolysaccharide and beta-amyloid in cultured rat microglia. Neuroreport 9, 871-874 (1998).
71. Baik, S. H. et al. Migration of neutrophils targeting amyloid plaques in Alzheimers disease mouse model. Neurobiol. Aging 35, 1286-1292 (2014).